Hong Kong's PAG to Invest $200 Million in U.S. RK Pharma

Hong Kongese alternative investment firm PAG is set to invest up to $200 million in RK Pharma, a U.S.-based pharmaceutical company with subsidiaries in India. Specializing in generic pharmaceutical products, particularly complex injectables, RK Pharma operates a Sterile Drug Product Manufacturing facility in Pearl River, New York. The deal marks PAG's fifth India-focused private equity investment, following successful ventures with Nuvama, Gamot API, and Acme Formulation. With over $1.5 billion invested in India in recent years, PAG continues to strengthen its presence in the Indian market.

In summary, Hong Kong's PAG is making a significant investment of up to $200 million in RK Pharma, a US-based pharmaceutical company with subsidiaries in India. RK Pharma specializes in generic pharmaceuticals, particularly complex injectables, and owns a Sterile Drug Product Manufacturing facility in Pearl River, New York. This deal represents PAG's fifth India-focused private equity investment, showcasing the firm's commitment to the Indian market, where it has invested over $1.5 billion in recent years.